DE60143320D1 - Mittel und methoden für die diagnose, behandlung und vorbeugung von auf steroid hormone reagierende krebskrankheiten - Google Patents
Mittel und methoden für die diagnose, behandlung und vorbeugung von auf steroid hormone reagierende krebskrankheitenInfo
- Publication number
- DE60143320D1 DE60143320D1 DE60143320T DE60143320T DE60143320D1 DE 60143320 D1 DE60143320 D1 DE 60143320D1 DE 60143320 T DE60143320 T DE 60143320T DE 60143320 T DE60143320 T DE 60143320T DE 60143320 D1 DE60143320 D1 DE 60143320D1
- Authority
- DE
- Germany
- Prior art keywords
- methods
- steroid hormone
- diagnosis
- prevention
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0629—Keratinocytes; Whole skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0631—Mammary cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
- C12N2501/392—Sexual steroids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/395—Thyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20331400P | 2000-05-10 | 2000-05-10 | |
US20834800P | 2000-05-31 | 2000-05-31 | |
US20811100P | 2000-05-31 | 2000-05-31 | |
US22907100P | 2000-08-30 | 2000-08-30 | |
US23127300P | 2000-09-08 | 2000-09-08 | |
PCT/US2001/015171 WO2001086307A2 (en) | 2000-05-10 | 2001-05-10 | Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60143320D1 true DE60143320D1 (de) | 2010-12-02 |
Family
ID=27539481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60143320T Expired - Lifetime DE60143320D1 (de) | 2000-05-10 | 2001-05-10 | Mittel und methoden für die diagnose, behandlung und vorbeugung von auf steroid hormone reagierende krebskrankheiten |
Country Status (8)
Country | Link |
---|---|
US (4) | US7947463B2 (de) |
EP (5) | EP1366366B1 (de) |
AT (2) | ATE485520T1 (de) |
AU (2) | AU2001272908A1 (de) |
CA (2) | CA2409765A1 (de) |
DE (1) | DE60143320D1 (de) |
MX (2) | MXPA02011092A (de) |
WO (2) | WO2001085210A2 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2409765A1 (en) | 2000-05-10 | 2001-11-15 | David A. Sirbasku | Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth |
US20030072812A1 (en) * | 2001-05-10 | 2003-04-17 | Sirbasku David A | Breast cancer eradication program |
US7863011B2 (en) * | 2000-05-10 | 2011-01-04 | Signe Biopharma, Inc. | Screening method for predicting susceptibility to breast cancer |
US8119138B2 (en) * | 2000-05-10 | 2012-02-21 | Signe Biopharma Inc. | Anti-estrogen and immune modulator combinations for treating breast cancer |
US20030104475A1 (en) * | 2001-06-28 | 2003-06-05 | Kelly Scott D. | Method and apparatus for computer modeling of an adaptive immune response |
AU2002343714A1 (en) | 2001-11-13 | 2003-05-26 | David A. Sirbasku | Breast cancer eradication program |
WO2003042660A2 (en) * | 2001-11-14 | 2003-05-22 | Sirbasku David A | Screening method for predicting susceptibility to breast cancer |
WO2003041654A2 (en) * | 2001-11-14 | 2003-05-22 | Sirbasku David A | Anti-estrogen and immune modulator combinations for treating breast cancer |
US7364846B2 (en) * | 2002-10-11 | 2008-04-29 | Molecular Devices Corporation | Gene expression profiling from FFPE samples |
EP2471922A1 (de) * | 2004-05-28 | 2012-07-04 | Asuragen, Inc. | Verfahren und Zusammensetzungen mit microRNA |
WO2008073922A2 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Functions and targets of let-7 micro rnas |
EP2322616A1 (de) | 2004-11-12 | 2011-05-18 | Asuragen, Inc. | Verfahren und Zusammensetzungen, die miRNAs und miRNA-inhibitorischen Molekülen verbunden sind |
US7485448B2 (en) * | 2005-09-13 | 2009-02-03 | Takara Bio Inc. | Serum-free medium for producing retroviruses |
WO2008036776A2 (en) * | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
US20090131348A1 (en) * | 2006-09-19 | 2009-05-21 | Emmanuel Labourier | Micrornas differentially expressed in pancreatic diseases and uses thereof |
WO2008073920A2 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-21 regulated genes and pathways as targets for therapeutic intervention |
CN101627121A (zh) * | 2006-12-08 | 2010-01-13 | 奥斯瑞根公司 | 作为治疗干预的靶标的miRNA调控基因和路径 |
US8709413B2 (en) * | 2006-12-13 | 2014-04-29 | Michael R. Simon | Treatment of celiac disease with IgA |
US20090175827A1 (en) * | 2006-12-29 | 2009-07-09 | Byrom Mike W | miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
US20090131354A1 (en) * | 2007-05-22 | 2009-05-21 | Bader Andreas G | miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
US20090232893A1 (en) * | 2007-05-22 | 2009-09-17 | Bader Andreas G | miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
US8015145B2 (en) * | 2007-06-05 | 2011-09-06 | Siemens Medical Solutions Usa, Inc. | System for providing healthcare operation specific user interface display images |
JP2010529966A (ja) * | 2007-06-08 | 2010-09-02 | アシュラジェン インコーポレイテッド | 治療的介入の標的としてmiR−34によって調節される遺伝子および経路 |
US8361714B2 (en) | 2007-09-14 | 2013-01-29 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
US20090186015A1 (en) * | 2007-10-18 | 2009-07-23 | Latham Gary J | Micrornas differentially expressed in lung diseases and uses thereof |
US8071562B2 (en) * | 2007-12-01 | 2011-12-06 | Mirna Therapeutics, Inc. | MiR-124 regulated genes and pathways as targets for therapeutic intervention |
US20090192114A1 (en) * | 2007-12-21 | 2009-07-30 | Dmitriy Ovcharenko | miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention |
US20090193338A1 (en) * | 2008-01-28 | 2009-07-30 | Trevor Fiatal | Reducing network and battery consumption during content delivery and playback |
US20090263803A1 (en) * | 2008-02-08 | 2009-10-22 | Sylvie Beaudenon | Mirnas differentially expressed in lymph nodes from cancer patients |
US20090233297A1 (en) * | 2008-03-06 | 2009-09-17 | Elizabeth Mambo | Microrna markers for recurrence of colorectal cancer |
EP2271757A2 (de) * | 2008-03-26 | 2011-01-12 | Asuragen, INC. | Zusammensetzungen und verfahren in zusammenhang mit mir-16 und prostatakrebstherapie |
US8258111B2 (en) | 2008-05-08 | 2012-09-04 | The Johns Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
US20100179213A1 (en) * | 2008-11-11 | 2010-07-15 | Mirna Therapeutics, Inc. | Methods and Compositions Involving miRNAs In Cancer Stem Cells |
JP2012530133A (ja) * | 2009-06-16 | 2012-11-29 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | 時間の経った赤血球の輸血に伴う副作用を改善するための方法 |
US8993347B2 (en) * | 2009-12-17 | 2015-03-31 | Cornell University | Methods for detecting antibodies in mucosal samples and device for sampling mucosal material |
US9644241B2 (en) | 2011-09-13 | 2017-05-09 | Interpace Diagnostics, Llc | Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease |
EP3049514B1 (de) * | 2013-09-24 | 2019-11-20 | University Of Miami | Zellkulturmedien |
HUE055693T2 (hu) | 2014-04-03 | 2021-12-28 | Igm Biosciences Inc | Módosított J-lánc |
KR20230130148A (ko) | 2015-03-04 | 2023-09-11 | 아이쥐엠 바이오사이언스 인코포레이티드 | Cd20 결합 분자 및 그의 용도 |
US10618978B2 (en) | 2015-09-30 | 2020-04-14 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
CN108463472A (zh) * | 2015-09-30 | 2018-08-28 | Igm生物科学有限公司 | 具有修饰的j-链的结合分子 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4393071A (en) | 1975-03-17 | 1983-07-12 | Naoharu Fujii | Method of treating gastric, mammary, lung and uterus tumors |
FR2558373B1 (fr) | 1984-01-20 | 1987-07-03 | Mauvais Jarvis Pierre | Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee |
US4683200A (en) | 1984-05-17 | 1987-07-28 | Setsuo Hirohashi | Monoclonal antibody to human cancer antigen and method for producing same |
GB8607137D0 (en) | 1986-03-21 | 1986-04-30 | Efamol Ltd | Compositions |
US5135849A (en) | 1986-04-17 | 1992-08-04 | Trustees Of Tufts College | In-vitro methods for identifying compositions which are agonists and antagonists of androgens |
US4859585A (en) * | 1986-04-17 | 1989-08-22 | Trustees Of Tufts College | In-vitro methods for identifying compositions which are agonists and antagonists of estrogens |
GB8628104D0 (en) * | 1986-11-25 | 1986-12-31 | Connaught Lab | Pasteurization of immunoglobin solutions |
US5980896A (en) | 1989-06-30 | 1999-11-09 | Bristol-Myers Squibb Company | Antibodies reactive with human carcinomas |
DE3927112C1 (de) | 1989-08-17 | 1990-10-25 | Biotest Pharma Gmbh, 6072 Dreieich, De | |
CN1057785A (zh) | 1990-04-16 | 1992-01-15 | 哈佛大学校长及研究员协会 | 合成多聚免疫球蛋白受体,受体-抗体复合物,生产及应用 |
RU1837891C (ru) | 1991-01-31 | 1993-08-30 | Keshelava Viktor V | Способ получени противоопухолевого средства |
WO1992013500A1 (en) | 1991-02-08 | 1992-08-20 | Surgical Innovations, Inc. | Method and apparatus for repair of inguinal hernias |
US6200547B1 (en) | 1994-01-26 | 2001-03-13 | Ferx Incorporated | Magnetically responsive compositions for carrying biologically active substances and methods of production and use |
US5405772A (en) * | 1993-06-18 | 1995-04-11 | Amgen Inc. | Medium for long-term proliferation and development of cells |
US5641863A (en) * | 1993-09-30 | 1997-06-24 | University Of Pennsylvania | Chimeric IgG Fc receptors |
GB9320820D0 (en) * | 1993-10-08 | 1993-12-01 | Biokine Tech Ltd | Compounds for medicinal use |
JPH07238036A (ja) * | 1994-02-28 | 1995-09-12 | Green Cross Corp:The | 静注用グロブリン液状組成物のグロブリン二量体増加抑制方法 |
US5772995A (en) | 1994-07-18 | 1998-06-30 | Sidney Kimmel Cancer Center | Compositions and methods for enhanced tumor cell immunity in vivo |
US5866323A (en) * | 1995-04-07 | 1999-02-02 | Case Western Reserve University | Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors |
US6902743B1 (en) | 1995-05-22 | 2005-06-07 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix |
AU6477196A (en) | 1995-06-07 | 1996-12-30 | Washington University | Multidentate metal complexes and methods of making and using thereof |
WO1997046715A1 (en) * | 1996-06-03 | 1997-12-11 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Fc receptor polymorphism |
AU730749B2 (en) * | 1996-07-25 | 2001-03-15 | Genzyme Corporation | Chondrocyte media formulations and culture procedures |
EP2243827B2 (de) | 1996-08-30 | 2017-11-22 | Life Technologies Corporation | Serumfreies kulturmedium für säugerzellen und seine verwendung |
WO1999005171A1 (en) * | 1997-07-28 | 1999-02-04 | Yale University | NOVEL ESTROGEN RECEPTOR β AND ISOFORMS |
US6020161A (en) | 1997-08-19 | 2000-02-01 | Smithkline Beecham Corporation | PIGR-1, a member of immunoglobulin gene superfamily |
JP2002507387A (ja) | 1997-12-24 | 2002-03-12 | コリクサ コーポレイション | 乳癌の免疫療法および診断のための化合物ならびにそれらの使用のための方法 |
AU5226999A (en) * | 1998-07-24 | 2000-02-14 | Uab Research Foundation | Genetic polymorphism in the receptor for iga |
IL125608A0 (en) * | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
AU1467900A (en) | 1998-11-06 | 2000-05-29 | Hospital For Sick Children, The | Chromosome 17p-linked prostate cancer susceptibility gene |
ES2581239T3 (es) | 1999-11-29 | 2016-09-02 | The Trustees Of Columbia University In The City Of New York | Aislamiento de cinco genes novedosos que codifican nuevos melanomas de tipo receptor de Fc implicados en la patogénesis del linfoma/melanoma |
JP2003523404A (ja) | 2000-02-25 | 2003-08-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 乳癌における治療に対する膜エストロゲンレセプター |
US6763307B2 (en) | 2000-03-06 | 2004-07-13 | Bioseek, Inc. | Patient classification |
AU2001252970A1 (en) | 2000-03-27 | 2001-10-08 | The Regents Of The University Of California | Ligands directed to the non-secretory component, non-stalk region of pIgR and methods of use thereof |
CA2409765A1 (en) | 2000-05-10 | 2001-11-15 | David A. Sirbasku | Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth |
US8119138B2 (en) | 2000-05-10 | 2012-02-21 | Signe Biopharma Inc. | Anti-estrogen and immune modulator combinations for treating breast cancer |
AU2002343714A1 (en) | 2001-11-13 | 2003-05-26 | David A. Sirbasku | Breast cancer eradication program |
WO2003042660A2 (en) | 2001-11-14 | 2003-05-22 | Sirbasku David A | Screening method for predicting susceptibility to breast cancer |
-
2001
- 2001-05-10 CA CA002409765A patent/CA2409765A1/en not_active Abandoned
- 2001-05-10 MX MXPA02011092A patent/MXPA02011092A/es active IP Right Grant
- 2001-05-10 AT AT01952116T patent/ATE485520T1/de not_active IP Right Cessation
- 2001-05-10 AT AT01948216T patent/ATE545433T1/de active
- 2001-05-10 EP EP01952116A patent/EP1366366B1/de not_active Expired - Lifetime
- 2001-05-10 EP EP01948216A patent/EP1328293B1/de not_active Expired - Lifetime
- 2001-05-10 US US09/852,547 patent/US7947463B2/en not_active Expired - Fee Related
- 2001-05-10 EP EP10184646.7A patent/EP2394659B1/de not_active Expired - Lifetime
- 2001-05-10 CA CA002409150A patent/CA2409150A1/en not_active Abandoned
- 2001-05-10 US US09/852,958 patent/US7947275B2/en not_active Expired - Fee Related
- 2001-05-10 AU AU2001272908A patent/AU2001272908A1/en not_active Abandoned
- 2001-05-10 WO PCT/US2001/015183 patent/WO2001085210A2/en active Application Filing
- 2001-05-10 MX MXPA02011093A patent/MXPA02011093A/es active IP Right Grant
- 2001-05-10 EP EP10185003A patent/EP2394660A1/de not_active Ceased
- 2001-05-10 DE DE60143320T patent/DE60143320D1/de not_active Expired - Lifetime
- 2001-05-10 EP EP10184776A patent/EP2359857A3/de not_active Withdrawn
- 2001-05-10 AU AU2001269690A patent/AU2001269690A1/en not_active Abandoned
- 2001-05-10 WO PCT/US2001/015171 patent/WO2001086307A2/en active Application Filing
-
2011
- 2011-05-20 US US13/112,444 patent/US8563249B2/en not_active Expired - Fee Related
- 2011-05-20 US US13/112,391 patent/US20120115161A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2409150A1 (en) | 2001-11-15 |
CA2409765A1 (en) | 2001-11-15 |
EP2394659A1 (de) | 2011-12-14 |
EP1366366B1 (de) | 2010-10-20 |
US20120028258A1 (en) | 2012-02-02 |
EP2394659B1 (de) | 2014-01-22 |
WO2001086307A3 (en) | 2003-10-02 |
MXPA02011092A (es) | 2004-08-19 |
US7947463B2 (en) | 2011-05-24 |
US20020012954A1 (en) | 2002-01-31 |
MXPA02011093A (es) | 2004-08-19 |
AU2001269690A1 (en) | 2001-11-20 |
US8563249B2 (en) | 2013-10-22 |
ATE485520T1 (de) | 2010-11-15 |
EP1328293A2 (de) | 2003-07-23 |
US20120115161A1 (en) | 2012-05-10 |
WO2001085210A3 (en) | 2003-04-17 |
US7947275B2 (en) | 2011-05-24 |
ATE545433T1 (de) | 2012-03-15 |
EP1328293B1 (de) | 2012-02-15 |
EP1366366A2 (de) | 2003-12-03 |
EP2359857A2 (de) | 2011-08-24 |
EP2394660A1 (de) | 2011-12-14 |
WO2001086307A2 (en) | 2001-11-15 |
EP2359857A3 (de) | 2012-02-22 |
US20020006630A1 (en) | 2002-01-17 |
WO2001085210A2 (en) | 2001-11-15 |
AU2001272908A1 (en) | 2001-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60143320D1 (de) | Mittel und methoden für die diagnose, behandlung und vorbeugung von auf steroid hormone reagierende krebskrankheiten | |
NZ330887A (en) | Monoclonals and polyclonals antibodies for the diagnosis of breast cancer | |
HK1038498A1 (en) | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids | |
WO2001008636A8 (en) | Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein | |
EP1892306A3 (de) | Verfahren und Kit zur Untersuchung von Krebs | |
ATE229073T1 (de) | Protein e25a, methoden zu dessen herstellung und anwendung | |
TR199903154T2 (xx) | Meme kanserinin tedavisi ve te�hisi i�in bile�imler ve y�ntemler | |
ATE336506T1 (de) | Verwendung löslicher cytokeratin-1-fragmente in diagnostik | |
TW200640944A (en) | VGF polypeptides and methods of treating VGF-related disorders | |
WO2006037485A3 (en) | Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy | |
Becker et al. | Gamma-globulin in the trabecular meshwork of glaucomatous eyes | |
AU2001233913A1 (en) | Bcmp 84, a protein associated to breast cancer | |
BR0311146A (pt) | Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino | |
Zanon et al. | Palliative treatment of malignant refractory ascites by positioning of Denver peritoneovenous shunt | |
ATE506961T1 (de) | Ccn3 proteine zur behandlung und diagnose von nierenerkrankungen | |
DE60113968D1 (de) | Diagnose von brustkrebs unter verwendung von bcmp-7 als marker | |
Krco et al. | Priapism due to solid malignancy | |
DE60032333D1 (de) | Zusammensetzungen und verfahren zur intraductalen gentherapie | |
ATE373711T1 (de) | Gewebe-spezifische protein 103p2d6, hochexprimiert in verschiedene krebsarten | |
Aktuğ et al. | Outpatient catheterless Mathieu repair: how to cover ventral penile skin defect | |
RU2408399C1 (ru) | Способ лечения доброкачественной гиперплазии предстательной железы | |
Kim et al. | Metastatic carcinoma of oral cavity | |
Pannek et al. | Fear of risks of cure in the treatment of a giant germ cell tumour: A case report | |
Yuan et al. | Case Report A case of suprapubic cutaneous metastasis from prostatic adenocarcinoma | |
Flocks | Carcinoma of the Prostate |